Metformin can enhance the apoptosis of CML cells induced by nilotinib and restore the sensitivity of drug-resistant cells to nilotinib by reducing Jun N-terminal kinase (JNK) phosphorylation and inhibiting Bcl-xl expression. Here, MAPK8 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.